Incretin Atlas › Molecules › HRS-4729
HRS-4729
GIP/GLP-1/GCG · s.c. · Hengrui
Summary
- Also known as
- Hengrui
- Mechanism
- GIP/GLP-1/GCG
- Route
- s.c.
- Company
- Hengrui
- Highest development stage
- phase 2
- Status (as of data cut)
- Phase 2 master protocol in MASH recruiting since Aug 2026; phase 1 at EASD 2026 verify
- Next milestone
- Phase 2 results
Sources for the status
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HRS-4729 phase 1 SAD/MAD, MAD part (NCT06762600) | 12 mg | obesity china | 12 | 60 | — | —−16.0 % vs −5.4 % estimand not specified | — | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (1)
- 12 mg · weight_unsp · press release
participants receiving multiple doses of 12 mg of HRS-4729 achieved a mean weight loss of up to 16.0% from baseline, compared to 5.4% with placebo.
Registered trials (1)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| NCT07660848 A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis | MASH | Phase 2 | recruiting | 2026-08 → 2028-03 | 160 | recruiting | NCT07660848 |
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: HRS-4729. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/hrs-4729/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.